A Study of Soticlestat in Adults and Children With Rare Epilepsies

Phase 2 Terminated NCT03635073

Summary

The main aim is to assess the long-term safety and tolerability of soticlestat when used along with other anti-seizure treatment. Participants will receive soticlestat twice a day. Participants will visit the study clinic every 2-6 months throughout the study. Study treatments may continue as long as the participant is receiving benefit from it.

Percentage of Participants Who Experienced At Least One Treatment-emergent Adverse Event (AE)

From screening up to end of the study (up to approximately 84 months) · percentage of participants

Change From Baseline in Behavioral and Adaptive Functional Measures Using the Vineland Adaptive Behavior Scale (VABS)

Baseline, Week 338 · score on a scale

Change From Baseline in Behavior Measures Using Total Scores of the Aberrant Behavior Checklist-Community Edition (ABC-C) for Participants Greater Than Equal to (≥) 6 Years of Age

Baseline, Week 338 · score on a scale

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

• Safety and Efficacy of tPBM for Epileptiform Activity in Autism — Richard Frye
• Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Th — SK Life Science, Inc.
• Sphenopalatine Ganglion Nerve Block vs. Elavil for Treatment of Transformed Migraines — Rutgers, The State University of New Jersey
• Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagno — University of Virginia
• A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or — Takeda
• Maintenance TMS in Treatment Resistant Depression — Austin Messner

All trials